4. Human emotion and reaction

The chart above illustrates the long-term performance divergence between the biotechnology sector and the broader NASDAQ market from the late 1990s through 2025. While the original 1998–2002 comparison showed dramatic flip-flops driven largely by speculation, the modern data reveal a similar—but more complex—pattern stretching across multiple market cycles.
In the early 2000s, biotech and technology stocks moved in opposing directions, with each sector experiencing sharp rallies and painful reversals. Yet, just as in that earlier period, these movements had little to do with fundamental changes inside the companies themselves. Instead, sentiment, hype, and macroeconomic forces dictated most of the price behavior.
Fast-forward to the 2020s, and a comparable dynamic re-emerges. Biotech stocks surged during the pandemic boom of 2020–2021, driven by vaccine breakthroughs, record funding, and aggressive retail speculation. Meanwhile, the NASDAQ soared even higher due to the explosive growth of large-cap technology firms.
But beginning in 2022, the two groups sharply diverged again:

• Biotech entered a deep, multi-year bear market, with many early-stage companies losing 50–80% of their value despite steady pipelines and strong scientific progress.
  
• Technology stocks continued to climb, eventually reaching new highs by 2023–2024 on the back of AI-driven optimism and megacap dominance.
  
• Only in 2025 did biotech begin a significant recovery, supported by renewed M&A, falling interest rates, improved regulatory visibility, and a normalization of valuations.
  

Just like in the earlier 1998–2002 example, this modern performance gap had little to do with the true condition of the businesses. Many biotech firms continued to advance research, earn approvals, and make scientific progress, yet their stock prices languished. Meanwhile, large technology companies—representing a disproportionate share of the NASDAQ—were rewarded with exceptional multiples regardless of near-term earnings volatility.
The major lesson remains unchanged: sector performance often diverges wildly from fundamentals. Market cycles, sentiment tides, liquidity conditions, and speculative flows can overpower underlying value for years at a time.
And just as before, a simple “buy-and-hold” approach in either sector would have produced mixed results. Long-term returns were dominated not by fundamentals, but by timing: entering or exiting during extreme sentiment swings had far more impact than the earnings power or scientific output of the companies involved.
In short, the updated chart reinforces the same conclusion the original author reached two decades ago:
investors often end up trading speculation itself—rather than the true value behind the companies.